Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could ...

An experimental muscle-preserving drug called bimagrumab helped people taking semaglutide (Ozempic/Wegovy) keep their muscle ...

TUESDAY, June 24, 2025 (HealthDay News) — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Under Lilly’s savings-card program for commercially insured people who lack coverage for Zepbound, a one-month prescription for Zepbound pens now costs a minimum of $650, up from $550 previously.

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.